CONTEXT: Carney complex (CNC) is a rare disease inherited as an autosomal dominant trait, associated with various tumors, and caused most frequently by inactivation of the PRKAR1A gene. OBJECTIVES: In our recent investigation of a large cohort of CNC patients, we identified several cases of pancreatic neoplasms. This possible association and PRKAR1A's possible involvement in pancreatic tumor have not been reported previously. PATIENTS AND METHODS: Nine patients (2.5%) with CNC and pancreatic neoplasms in an international cohort of 354 CNC patients were identified; we studied six of them. Immunohistochemistry and PRKAR1A sequencing were obtained. RESULTS: Three men and three women with a mean age of 49 yr (range 34-75 yr) had acinar cell carcinoma (n = 2), adenocarcinoma (n = 1), and intraductal pancreatic mucinous neoplasm (n = 3). Five patients had a germline PRKAR1A mutation, including two patients with acinar cell carcinoma, for whom mutations were found in a hemizygous state in the tumor, suggesting loss of heterozygosity. PRKAR1A expression was not detected in five of the six pancreatic neoplasms from CNC patients, whereas the protein was amply expressed on other sporadic pancreatic tumors and normal tissue. CONCLUSION: An unexpectedly high prevalence of rare pancreatic tumors was found among CNC patients. Immunohistochemistry and loss-of-heterozygosity studies suggest that PRKAR1A could function as a tumor suppressor gene in pancreatic tissue, at least in the context of CNC. Clinicians taking care of CNC patients should be aware of the possible association of CNC with a potentially aggressive pancreatic neoplasm.
CONTEXT: Carney complex (CNC) is a rare disease inherited as an autosomal dominant trait, associated with various tumors, and caused most frequently by inactivation of the PRKAR1A gene. OBJECTIVES: In our recent investigation of a large cohort of CNC patients, we identified several cases of pancreatic neoplasms. This possible association and PRKAR1A's possible involvement in pancreatic tumor have not been reported previously. PATIENTS AND METHODS: Nine patients (2.5%) with CNC and pancreatic neoplasms in an international cohort of 354 CNC patients were identified; we studied six of them. Immunohistochemistry and PRKAR1A sequencing were obtained. RESULTS: Three men and three women with a mean age of 49 yr (range 34-75 yr) had acinar cell carcinoma (n = 2), adenocarcinoma (n = 1), and intraductal pancreatic mucinous neoplasm (n = 3). Five patients had a germline PRKAR1A mutation, including two patients with acinar cell carcinoma, for whom mutations were found in a hemizygous state in the tumor, suggesting loss of heterozygosity. PRKAR1A expression was not detected in five of the six pancreatic neoplasms from CNC patients, whereas the protein was amply expressed on other sporadic pancreatic tumors and normal tissue. CONCLUSION: An unexpectedly high prevalence of rare pancreatic tumors was found among CNC patients. Immunohistochemistry and loss-of-heterozygosity studies suggest that PRKAR1A could function as a tumor suppressor gene in pancreatic tissue, at least in the context of CNC. Clinicians taking care of CNC patients should be aware of the possible association of CNC with a potentially aggressive pancreatic neoplasm.
Authors: M Casey; C J Vaughan; J He; C J Hatcher; J M Winter; S Weremowicz; K Montgomery; R Kucherlapati; C C Morton; C T Basson Journal: J Clin Invest Date: 2000-09 Impact factor: 14.808
Authors: L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: Emmy Ludwig; Sara H Olson; Sharon Bayuga; Jennifer Simon; Mark A Schattner; Hans Gerdes; Peter J Allen; William R Jarnagin; Robert C Kurtz Journal: Am J Gastroenterol Date: 2011-04-05 Impact factor: 10.864
Authors: Sébastien Gaujoux; Murray F Brennan; Mithat Gonen; Michael I D'Angelica; Ronald DeMatteo; Yuman Fong; Mark Schattner; Christopher DiMaio; Maria Janakos; William R Jarnagin; Peter J Allen Journal: J Am Coll Surg Date: 2011-04 Impact factor: 6.113
Authors: G Rigaud; P S Moore; G Zamboni; S Orlandini; D Taruscio; S Paradisi; N R Lemoine; G Klöppel; A Scarpa Journal: Int J Cancer Date: 2000-12-01 Impact factor: 7.396
Authors: Susan C Abraham; David S Klimstra; Robb E Wilentz; Charles J Yeo; Kevin Conlon; Murray Brennan; John L Cameron; Tsung-Teh Wu; Ralph H Hruban Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Susan C Abraham; Tsung-Teh Wu; Ralph H Hruban; Jae-Hyuk Lee; Charles J Yeo; Kevin Conlon; Murray Brennan; John L Cameron; David S Klimstra Journal: Am J Pathol Date: 2002-03 Impact factor: 4.307
Authors: Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders Journal: Eur J Endocrinol Date: 2012-12-10 Impact factor: 6.664
Authors: Gabrielle A Yeaney; Jillene M Brathwaite; Matthew L Dashnaw; G Edward Vates; Laura M Calvi Journal: Endocr Pathol Date: 2013-06 Impact factor: 3.943